A pill for inherited dementia raised a key brain protein in its first human trial

A pill aimed at one inherited form of dementia has cleared its first test in people, and it did what scientists hoped. It is not a treatment you can get today, but it is a real step toward one for families who live with this disease.

The pill is called VES001. In a trial with 79 healthy adults, it was well tolerated and raised progranulin, a protein that is too low in people with a genetic form of frontotemporal dementia. The protein went up in the blood and in the fluid around the brain.

How the study worked

This was a first-in-human trial. Researchers gave 79 healthy adults, with an average age of 28, either VES001 or a placebo, and nobody knew who got which. Some people took a single dose, and others took the pill for 7 days. The results appeared in Nature Communications on Sept. 14, 2026. The groups were small and the volunteers were healthy, so this trial shows how the drug behaves in the body rather than how it treats the disease.

What they found

The pill was safe and well tolerated. There were no deaths, no serious side effects, and no one stopped taking it because of the drug. Headache and fatigue were mild and did not get worse with higher doses.

The pill also reached the brain. It crossed the blood-brain barrier, the tight filter that keeps most medicines out of the brain.

And it raised progranulin. With the pill taken twice a day, progranulin rose and stayed up compared with placebo. In blood, the peak increase was about 49% above where people started. In spinal fluid, which bathes the brain, the increase was about 18%.

In the paper’s exact numbers, that is a 49% peak change in blood plasma and an 18% change in cerebrospinal fluid.

Why progranulin matters

One inherited form of frontotemporal dementia comes from changes in a gene called GRN. People with these changes make too little progranulin. A receptor called sortilin clears progranulin out of circulation. VES001 blocks sortilin, so more progranulin stays around.

There is no approved treatment that slows frontotemporal dementia today. Showing that a pill can raise this protein safely in people is a necessary first step before testing whether it helps those who carry the gene change.

What you can do today

If frontotemporal dementia runs in your family, write down which relatives had it, how old they were when symptoms began, and what the first signs were. A short list like that gives a genetics counselor or a memory clinic a strong place to start. Carriers of a GRN change may be able to join future trials of drugs like this one.